News - Dermatologicals, Stelara Injection

Filter

Popular Filters

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study

08-07-2013

Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Back to top